Add BrightSurf on Google Email

Delayed access to tertiary care associated with higher death rate from type of pulmonary fibrosis

Patients with idiopathic pulmonary fibrosis (IPF) face a higher risk of death when accessing tertiary care centers, according to recent research. Early detection and referral methods can shorten the time from symptoms onset to referral, ultimately improving patient outcomes.

SourceColumbia University Irving Medical Center·JournalAmerican Journal of Respiratory and Critical Care Medicine·DateJul 1, 2011

Exposure to parental stress increases pollution-related lung damage in children

Research finds that growing up in a stressful household is associated with larger traffic pollution-induced lung deficits in healthy children. High levels of perceived stress among parents, particularly Hispanic and Asian families, led to decreased lung function in children exposed to traffic-related pollutants.

SourceAmerican Thoracic Society·JournalAmerican Journal of Respiratory and Critical Care Medicine·DateJun 24, 2011

Circulating levels of a lung protein found to be 'strongly predictive' of cardiovascular disease

A study found that circulating levels of surfactant protein-D were associated with cardiovascular disease and mortality in patients with coronary artery disease, independent of other risk factors. Blood levels of SP-D increase when the lungs are inflamed, such as in smokers or those with chronic lung conditions like COPD.

SourceEuropean Society of Cardiology·JournalEuropean Heart Journal·DateJun 8, 2011

JCI table of contents: May 23, 2011

Researchers identified a new probiotic bacteria-derived soluble protein that can protect intestinal cells from inflammation and injury in mice models of colitis. The protein's delivery to the colon provided therapeutic protection against ulcerative intestinal inflammatory disorders.

SourceJCI Journals·JournalJournal of Clinical Investigation·DateMay 23, 2011

Pirfenidone reduces rate of lung decline in idiopathic pulmonary fibrosis, raising hope for many thousands of patents

Pirfenidone reduces lung function decline in idiopathic pulmonary fibrosis patients, showing a clinically meaningful benefit and favourable safety profile. The treatment has been approved for mild to moderate idiopathic pulmonary fibrosis in Europe and shows promise for the estimated 100,000 people affected across the continent.

SourceThe Lancet_DELETED·JournalThe Lancet·DateMay 13, 2011

Reducing the side effects of a multiple sclerosis drug

A team of researchers has detailed the molecular mechanism by which FTY270 causes adverse effects in the lungs of mice with multiple sclerosis. The study suggests that developing a drug targeting S1P receptors on immune cells could provide a therapeutic with decreased side effects.

SourceJCI Journals·JournalJournal of Clinical Investigation·DateMay 9, 2011

JCI online early table of contents: May 2, 2011

Researchers discovered that immune cells play a crucial role in the worsening of atopic dermatitis when exposed to food allergens, with implications for prevention and treatment. Additionally, studies identified TIF1-gamma as a tumor suppressor in mouse and human chronic myelomonocytic leukemia.

SourceJCI Journals·JournalJournal of Clinical Investigation·DateMay 2, 2011

IPF drug fails in new trial

A new study found that taking bosentan did not improve health outcomes for patients with idiopathic pulmonary fibrosis (IPF). Researchers suggest a subset of IPF patients may still benefit from the drug, but further studies are needed to confirm this.

SourceAmerican Thoracic Society·JournalAmerican Journal of Respiratory and Critical Care Medicine·DateApr 8, 2011

ATS issues joint statement on the treatment of idiopathic pulmonary fibrosis

The American Thoracic Society has released updated guidelines for diagnosing and managing idiopathic pulmonary fibrosis (IPF), a chronic and progressive lung disease. The new guidelines emphasize evidence-based recommendations for diagnosis, pharmacologic and non-pharmacologic therapies, and palliative care.

SourceAmerican Thoracic Society·JournalAmerican Journal of Respiratory and Critical Care Medicine·DateMar 17, 2011

Sirolimus therapy alleviates symptoms of lung disease LAM

A new study sponsored by the National Heart, Lung, and Blood Institute found that sirolimus therapy can improve lung function and quality of life in individuals with lymphangioleiomyomatosis (LAM). The treatment was shown to slow disease progression and improve clinical outcomes in patients with this rare and progressive lung disease.

SourceNIH/National Heart, Lung and Blood Institute·JournalNew England Journal of Medicine·DateMar 16, 2011

New therapy found for rare lung disorder

Researchers at University of Cincinnati have found that sirolimus stabilizes lung function in women with lymphangioleiomyomatosis (LAM), a progressive and cystic lung disease. The Multicenter International LAM Efficacy of Sirolimus trial showed improved measures of functional performance, quality of life, and reduced VEGF-D levels.

SourceUniversity of Cincinnati·JournalNew England Journal of Medicine·DateMar 16, 2011

Solving the riddle of nature's perfect spring

Researchers have discovered the structure of tropoelastin, a key component of elastin that provides elasticity to human tissues. The molecule has near-perfect elasticity, allowing it to stretch up to eight times its original length and return to its shape with no loss of energy.

SourceUniversity of Manchester·JournalProceedings of the National Academy of Sciences·DateMar 1, 2011

Viral infection not responsible for exacerbation of lung disease in most patients

Researchers found no evidence of viral infection causing acute exacerbation of idiopathic pulmonary fibrosis (IPF) in most patients. Instead, torque teno virus (TTV) was detected in lung fluid samples from a small percentage of IPF patients, suggesting it may be a marker of lung injury rather than a cause.

SourceAmerican Thoracic Society·JournalAmerican Journal of Respiratory and Critical Care Medicine·DateFeb 25, 2011

Vitamin D deficiency alters lung growth and decreases lung function

Researchers found that vitamin D-deficient mice had reduced lung volume, lower airway resistance, and smaller lungs compared to control mice. The study suggests a potential link between vitamin D deficiency and obstructive lung disease, highlighting the need for future studies on prevention and treatment strategies.

SourceAmerican Thoracic Society·JournalAmerican Journal of Respiratory and Critical Care Medicine·DateJan 28, 2011